Connect with us

OK NYMEX, Beginning To Notice The Fine Print?

Is it a building case of/for selling the news? Another substantial down day in the oil market brings the total slide to just more than 13% (since March 5). Hardly anything earth-shaking on its own, not with the WTI front month futures contract gaining…

Published

on

Is it a building case of/for selling the news? Another substantial down day in the oil market brings the total slide to just more than 13% (since March 5). Hardly anything earth-shaking on its own, not with the WTI front month futures contract gaining an impressive 85% since the end of October. During those four and a half months, the news was all good (or so it seemed) beginning in the world of pharma (vaccines) and spreading to politics (elections and what that was going to mean for “stimulus”).

So, up 85% and then down 13% isn’t at all outside the realm of prudent profit-taking following such a huge, nearly-vertical run.

It’s easy to think about and make future impacts into whatever you want from them; vaccines end the pandemic, and then Uncle Sam comprehensively cleans up its mess writing enormous checks. But when all these things actually happen, no longer future tense, it’s understandable this tendency to take a little off the table to wait and see if the dreams really do match reality.

If this was all that’s going on WTI-wise, a price correction, then it might not be worth much more than passing notation (already did that last week). But our suspicions only deepen right at the front of the crude oil futures curve – to begin with, the front-end, one-month calendar spread refuses to backward-ate.

The few pennies of reappearing contango right at the start could have been a technical artifact of the April 2021 contract becoming more and more illiquid as it neared expiration. With it off-the-board today, however, the one-month calendar spread remains (now between the May and June 2021 contracts).

And if that was all for the WTI curve, too, maybe it’d deserve barely a tiny bit more than a passing notation; it’s not.



What really gets my attention is as much the rest of the curve; just how far – really how fast – the backwardation has been drained right out of it. The selling is quick and violent in the front over the last week because of this flattening. Like yields and money curves, shape so often means as much or more in them as nominal price.

The numbers are substantial; beyond the very front contango, backwardation has really shrunk since the profit-taking/selloff picked up last Thursday. The calendar spread out to the end-of-year December contract, for instance, had puffed all the way out to $4.38 back on March 11, since cut down by well more than half really in just a few trading days ($1.77 as of this afternoon).

The spread to June of next year has collapsed from $7.39 on the 11th to just $3.39 today. In the current session, March 23, the front CL1 (May 2021) was down $4.04 (as of this writing) while the December 2021 maturity lost “only” $3.03 (and June 2022 was -$2.32).

That’s a whole lot of potentially meaningful flattening.



But why? The vertical take-off October to early March had been pricing perfection. In preparation for most Americans becoming first $600 and now $1400 “richer” (as the media says), enormous “stimulus”, why not bid oil to the moon? After all, supply isn’t coming back online, at all

Now that the first one is nearly three months behind, and the second is happening, along with increased vaccination, the dreamy optimism grows murkier; a bit more complicated when, where, and how the rubber meets the road. As noted yesterday, for one, booming, cash rich-fueled recoveries aren’t checked so easily and thoroughly by harsh winter weather no matter how harsh and wintry; the Chicago Fed’s National Activity Index and its February -1.09 should call a solid halt to thus-far unchallenged assumptions.

Beyond that and other data, when it comes to the “stimulus” details there’s plenty of concern when the plan revolves around – to the point of being almost completely dependent upon – “I’m from the government and I’m here to help!”

To that end, research firm Alignable published yesterday some sobering survey results of small and medium businesses, the very economic segments both bearing the brunt of the current recession as well as being the places where normal recovery first buds and then blooms.



If we’re thinking about what it is, exactly, the federal government is trying to overcome, but hasn’t come close yet, it’s lost jobs because of this:

– 41% of SMBs have a month or less of cash reserves left (up from 32% last month)
– 49% of SMBs couldn’t pay March rent in full, on time (up from 38% in February)
– 74% of small business owners are struggling to receive PPP funds (though 26% say the PPP has been fast and easy).

Only 16% of surveyed small businesses claimed “they’re doing fine and have no worries about keeping their businesses alive.” Barely one in six, economywide.

The whole point of the PPP, and its recent expansion, was, as I wrote above, to smooth over these huge holes in the economy. Big businesses, those easily able to float liquid debt instruments no matter how unsavory and uncreditworthy simply because there exists a reasonable (today) market for them, they don’t have to worry about such lingering insolvency issues and thus don’t really need more rescuing (at the present moment). Small firms either go to banks (which don’t want to lend) or have to place all their hopes upon frictionless stipends and grants – the very thing government does worst.

Some of the comments were, well, chafing:

“The PPP loan is hard to get. We’re SO FRUSTRATED! We train first responders and may not make it!”

“2019 was not a great year. Last year was better for my carpet cleaning business, but now I don’t qualify for the PPP when I really need it. In the first two months of the year, I also had COVID. I lost a lot of jobs because of it, and now when I really need the PPP, they won’t give it to me. The system stinks.”

“This application is a total nightmare.”

Small (and medium) businesses worried about survival aren’t in any shape (or mood) to be hiring back the multitudes of workers they let go starting a year ago now. Therefore, with the labor market having remained utterly gutted, guess what Americans said in February they plan to do with the Uncle Sam’s latest helicoptered gift (via Bloomberg):



That’s 50% between saving and paying down credit card debt (same thing), while another 50% in on food and housing (mostly back rent, presumably). There’s just about as much indicated to chase Bitcoin as buy electronics, each of those only a tiny bit. Stimulus?

The huge, thirteen-digit numbers they throw around when describing these monstrous “rescue” packages don’t quite look the same in the fine print (which is what happened to the CARES Act, the last thirteen-digit “rescue”). In the neo-Keynesian DSGE models popular with Economists and central bankers (same thing), they don’t actually model this sort of granular detail, preferring instead to presume some outlandish yet uniform “multiplier” effect derived from overly simplified assumptions (“spend $XXX hundred billion on near anything, the calculations indicate it will boost the economy by 1.2836987563 times the headline”).

The same thing the mainstream argued both for (it’s going to work well; recovery) and against (it’s going to work too well; inflationary) 2009’s ARRA. Reality (it doesn’t work at all; continued deflationary) is never presented as an option and markets being imperfect do forget from time to time (what is, after all, reflationary?)

Stimulus and vaccines, very easy to picture things going perfectly, and then trading such perfection, before they really get going. If it was as easy as the DSGE models have all said for as long as econometrics has been around then there’d only ever have been, or would ever be, just one QE or one fiscal “rescue.”

If “they” gotta keep doing them over and over and over, that isn’t something to unquestionably swallow (inflationary!) it’s a pretty clear indication the last one, like all the other last ones, didn’t work. Or, at the very least, it doesn’t work so easily and effectively as it is “supposed” to. These things get complicated; at times like these, complicated isn’t good and it doesn’t space out $7 bucks in longer-dated WTI contango. 

Maybe oil right now is just taking a breath; too soon to say for sure. But as news of the rubber meeting the road, and the WTI curve flattens ever further maybe even edging more of it eventually into contango, you really have to question the fine print (again).

Read More

Continue Reading

International

Analyst reviews Apple stock price target amid challenges

Here’s what could happen to Apple shares next.

Published

on

They said it was bound to happen.

It was Jan. 11, 2024 when software giant Microsoft  (MSFT)  briefly passed Apple  (AAPL)  as the most valuable company in the world.

Microsoft's stock closed 0.5% higher, giving it a market valuation of $2.859 trillion. 

It rose as much as 2% during the session and the company was briefly worth $2.903 trillion. Apple closed 0.3% lower, giving the company a market capitalization of $2.886 trillion. 

"It was inevitable that Microsoft would overtake Apple since Microsoft is growing faster and has more to benefit from the generative AI revolution," D.A. Davidson analyst Gil Luria said at the time, according to Reuters.

The two tech titans have jostled for top spot over the years and Microsoft was ahead at last check, with a market cap of $3.085 trillion, compared with Apple's value of $2.684 trillion.

Analysts noted that Apple had been dealing with weakening demand, including for the iPhone, the company’s main source of revenue. 

Demand in China, a major market, has slumped as the country's economy makes a slow recovery from the pandemic and competition from Huawei.

Sales in China of Apple's iPhone fell by 24% in the first six weeks of 2024 compared with a year earlier, according to research firm Counterpoint, as the company contended with stiff competition from a resurgent Huawei "while getting squeezed in the middle on aggressive pricing from the likes of OPPO, vivo and Xiaomi," said senior Analyst Mengmeng Zhang.

“Although the iPhone 15 is a great device, it has no significant upgrades from the previous version, so consumers feel fine holding on to the older-generation iPhones for now," he said.

A man scrolling through Netflix on an Apple iPad Pro. Photo by Phil Barker/Future Publishing via Getty Images.

Future Publishing/Getty Images

Big plans for China

Counterpoint said that the first six weeks of 2023 saw abnormally high numbers with significant unit sales being deferred from December 2022 due to production issues.

Apple is planning to open its eighth store in Shanghai – and its 47th across China – on March 21.

Related: Tech News Now: OpenAI says Musk contract 'never existed', Xiaomi's EV, and more

The company also plans to expand its research centre in Shanghai to support all of its product lines and open a new lab in southern tech hub Shenzhen later this year, according to the South China Morning Post.

Meanwhile, over in Europe, Apple announced changes to comply with the European Union's Digital Markets Act (DMA), which went into effect last week, Reuters reported on March 12.

Beginning this spring, software developers operating in Europe will be able to distribute apps to EU customers directly from their own websites instead of through the App Store.

"To reflect the DMA’s changes, users in the EU can install apps from alternative app marketplaces in iOS 17.4 and later," Apple said on its website, referring to the software platform that runs iPhones and iPads. 

"Users will be able to download an alternative marketplace app from the marketplace developer’s website," the company said.

Apple has also said it will appeal a $2 billion EU antitrust fine for thwarting competition from Spotify  (SPOT)  and other music streaming rivals via restrictions on the App Store.

The company's shares have suffered amid all this upheaval, but some analysts still see good things in Apple's future.

Bank of America Securities confirmed its positive stance on Apple, maintaining a buy rating with a steady price target of $225, according to Investing.com

The firm's analysis highlighted Apple's pricing strategy evolution since the introduction of the first iPhone in 2007, with initial prices set at $499 for the 4GB model and $599 for the 8GB model.

BofA said that Apple has consistently launched new iPhone models, including the Pro/Pro Max versions, to target the premium market. 

Analyst says Apple selloff 'overdone'

Concurrently, prices for previous models are typically reduced by about $100 with each new release. 

This strategy, coupled with installment plans from Apple and carriers, has contributed to the iPhone's installed base reaching a record 1.2 billion in 2023, the firm said.

More Tech Stocks:

Apple has effectively shifted its sales mix toward higher-value units despite experiencing slower unit sales, BofA said.

This trend is expected to persist and could help mitigate potential unit sales weaknesses, particularly in China. 

BofA also noted Apple's dominance in the high-end market, maintaining a market share of over 90% in the $1,000 and above price band for the past three years.

The firm also cited the anticipation of a multi-year iPhone cycle propelled by next-generation AI technology, robust services growth, and the potential for margin expansion.

On Monday, Evercore ISI analysts said they believed that the sell-off in the iPhone maker’s shares may be “overdone.”

The firm said that investors' growing preference for AI-focused stocks like Nvidia  (NVDA)  has led to a reallocation of funds away from Apple. 

In addition, Evercore said concerns over weakening demand in China, where Apple may be losing market share in the smartphone segment, have affected investor sentiment.

And then ongoing regulatory issues continue to have an impact on investor confidence in the world's second-biggest company.

“We think the sell-off is rather overdone, while we suspect there is strong valuation support at current levels to down 10%, there are three distinct drivers that could unlock upside on the stock from here – a) Cap allocation, b) AI inferencing, and c) Risk-off/defensive shift," the firm said in a research note.

Related: Veteran fund manager picks favorite stocks for 2024

Read More

Continue Reading

International

Major typhoid fever surveillance study in sub-Saharan Africa indicates need for the introduction of typhoid conjugate vaccines in endemic countries

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high…

Published

on

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

Credit: IVI

There is a high burden of typhoid fever in sub-Saharan African countries, according to a new study published today in The Lancet Global Health. This high burden combined with the threat of typhoid strains resistant to antibiotic treatment calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines (TCVs) in endemic settings along with improvements in access to safe water, sanitation, and hygiene.

 

The findings from this 4-year study, the Severe Typhoid in Africa (SETA) program, offers new typhoid fever burden estimates from six countries: Burkina Faso, Democratic Republic of the Congo (DRC), Ethiopia, Ghana, Madagascar, and Nigeria, with four countries recording more than 100 cases for every 100,000 person-years of observation, which is considered a high burden. The highest incidence of typhoid was found in DRC with 315 cases per 100,000 people while children between 2-14 years of age were shown to be at highest risk across all 25 study sites.

 

There are an estimated 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths. However, with generic symptoms such as fever, fatigue, and abdominal pain, and the need for blood culture sampling to make a definitive diagnosis, it is difficult for governments to capture the true burden of typhoid in their countries.

 

“Our goal through SETA was to address these gaps in typhoid disease burden data,” said lead author Dr. Florian Marks, Deputy Director General of the International Vaccine Institute (IVI). “Our estimates indicate that introduction of TCV in endemic settings would go to lengths in protecting communities, especially school-aged children, against this potentially deadly—but preventable—disease.”

 

In addition to disease incidence, this study also showed that the emergence of antimicrobial resistance (AMR) in Salmonella Typhi, the bacteria that causes typhoid fever, has led to more reliance beyond the traditional first line of antibiotic treatment. If left untreated, severe cases of the disease can lead to intestinal perforation and even death. This suggests that prevention through vaccination may play a critical role in not only protecting against typhoid fever but reducing the spread of drug-resistant strains of the bacteria.

 

There are two TCVs prequalified by the World Health Organization (WHO) and available through Gavi, the Vaccine Alliance. In February 2024, IVI and SK bioscience announced that a third TCV, SKYTyphoid™, also achieved WHO PQ, paving the way for public procurement and increasing the global supply.

 

Alongside the SETA disease burden study, IVI has been working with colleagues in three African countries to show the real-world impact of TCV vaccination. These studies include a cluster-randomized trial in Agogo, Ghana and two effectiveness studies following mass vaccination in Kisantu, DRC and Imerintsiatosika, Madagascar.

 

Dr. Birkneh Tilahun Tadesse, Associate Director General at IVI and Head of the Real-World Evidence Department, explains, “Through these vaccine effectiveness studies, we aim to show the full public health value of TCV in settings that are directly impacted by a high burden of typhoid fever.” He adds, “Our final objective of course is to eliminate typhoid or to at least reduce the burden to low incidence levels, and that’s what we are attempting in Fiji with an island-wide vaccination campaign.”

 

As more countries in typhoid endemic countries, namely in sub-Saharan Africa and South Asia, consider TCV in national immunization programs, these data will help inform evidence-based policy decisions around typhoid prevention and control.

 

###

 

About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO) and developed a new-generation typhoid conjugate vaccine that is recently pre-qualified by WHO.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, a Country Office in Austria, and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

CONTACT

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int


Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Trending